Press releases
Access archived Guidant press releases
Access archived BTG press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Aug 26, 2020
Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming virtual investor conferences. On September 9, 2020, Mike Mahoney, chairman and chief executive officer, and Susie Lisa,...
-
Jul 29, 2020
Boston Scientific Corporation (NYSE: BSX) generated sales of $2.003 billion during the second quarter of 2020. This represents a decline of (23.9) percent on a reported basis, (23.1) percent on an...
-
Jul 21, 2020New stroke risk reduction technology designed to advance procedural performance and safety, treat wider range of patients with non-valvular atrial fibrillation
Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. Experience...
-
Jun 30, 2020
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2020 on Wednesday, July 29,...
-
Jun 29, 2020First ICM device with remote programming paired with dual-stage arrhythmia detection algorithm
Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the LUX-Dx™ Insertable Cardiac Monitor (ICM) System, a new, long-term diagnostic device...
-
Jun 8, 2020
Boston Scientific (NYSE: BSX) today announced that the Centers for Medicare & Medicaid Services (CMS) has approved its application for a transitional pass-through (TPT) payment category to...
-
Jun 1, 2020Tool provides electrophysiologists with first-ever local measurement and visualization of tissue response to radiofrequency ablation
Boston Scientific (NYSE: BSX) announced the U.S. launch of the DIRECTSENSE™ Technology, a tool for monitoring the effect of radiofrequency (RF) energy delivery during cardiac ablation...
-
May 27, 2020
Boston Scientific Corporation (NYSE: BSX) completed the concurrent offerings of (i) 29,382,500 shares of its common stock, which includes the exercise in full by the underwriters of their option...
-
May 26, 2020
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Jefferies 2020 Virtual Healthcare Conference on June 2. Joe Fitzgerald, executive vice president and president, Rhythm...
-
May 21, 2020
Boston Scientific Corporation (NYSE: BSX) announced the pricing of concurrent offerings of 25,550,000 shares of its common stock ("Common Stock") at a price to the public of $34.25 per share and...
-
May 20, 2020
Boston Scientific Corporation (NYSE: BSX) announced that it has commenced concurrent offerings of $750.0 million of shares of its common stock ("Common Stock") and $750.0 million of shares of its...
-
May 18, 2020
Boston Scientific Corporation (NYSE: BSX) completed a public offering of $1.7 billion aggregate principal amount of its senior notes. The public offering consists of $500.0 million of 1.900% notes...
-
May 14, 2020
Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of $1.7 billion aggregate principal amount of its senior notes under the company's shelf registration...
-
May 8, 2020Trial meets primary safety and efficacy endpoints with low complication rates, 100% effective closure with next-generation stroke risk reduction technology for patients with non-valvular atrial fibrillation
Today, Boston Scientific (NYSE: BSX) announced positive 12-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the next-generation WATCHMAN FLX™ Left Atrial...
-
May 8, 2020Outcomes presented at HRS 2020 SCIENCE demonstrate device benefits for patients at risk of sudden cardiac death
Boston Scientific (NYSE: BSX) today announced the final results from the UNTOUCHED study of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System presented at HRS 2020 SCIENCE, an...
-
May 6, 2020
Boston Scientific Corporation (NYSE: BSX) will participate in three upcoming virtual investor conferences. On May 13, 2020, Dan Brennan, executive vice president and chief financial officer, and...
-
Apr 29, 2020
Boston Scientific Corporation (NYSE: BSX) generated sales of $2.543 billion during the first quarter of 2020. This represents growth of 2.0 percent on a reported basis, 3.2 percent on an...
-
Apr 21, 2020New energy deal puts Boston Scientific on pace to reach goal of carbon neutral manufacturing and operations
Boston Scientific Corporation (NYSE: BSX) has signed a virtual power purchase agreement (VPPA) that represents the largest step the company has taken to achieve its goal of global carbon neutral...
-
Apr 10, 2020
Boston Scientific Corporation (NYSE: BSX) today announced that its Annual Meeting of Stockholders (the "Annual Meeting") will be held exclusively in a virtual meeting format at the previously...
-
Apr 2, 2020
The COVID-19 pandemic has brought unprecedented challenges upon the global community and the many healthcare providers who are caring for patients. During this time of concern and disruption,...
-
Feb 18, 2020
Boston Scientific Corporation (NYSE: BSX) will participate in three upcoming investor conferences. On February 27, 2020, Susie Lisa, vice president, Investor Relations, will participate in a...
-
Feb 5, 2020
Boston Scientific Corporation (NYSE: BSX) generated sales of $2.905 billion during the fourth quarter of 2019. This represents growth of 13.4 percent on a reported basis, 14.1 percent on an...
-
Jan 14, 2020
Boston Scientific Corporation (NYSE: BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.90 billion during the fourth quarter of 2019. This represents...
-
Jan 2, 2020Conference schedule includes 38th Annual J.P. Morgan Healthcare Conference and Investor Update at NANS 2020
Boston Scientific Corporation (NYSE: BSX) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 in San Francisco, California. Mike Mahoney, chairman...
-
Dec 13, 2019U.S. Food and Drug Administration Granted EXALT Model D Single-Use Duodenoscope Breakthrough Device Designation, Expediting Physicians' Access to a New, Sterile Device for Each Patient
Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the EXALT™ Model D Single-Use Duodenoscope for use in endoscopic retrograde...